Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416847 | 1.00 | CTSK (0.52) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL16710005 | 0.98 | CTSK (0.51) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL1706223 | 0.89 | CTSK (0.64) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL1706224 | 0.89 | CTSK (0.64) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL9906163 | 0.89 | CTSK (0.64) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL19982034 | 0.88 | CTSK (0.62) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL27610791 | 0.88 | CTSK (0.62) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL16709994 | 0.88 | CTSK (0.62) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL15947741 | 0.87 | CTSK (0.50) | CTSKCTSLCTSBPREPKMT2A | |
| SCHEMBL9102129 | 0.86 | CTSK (0.60) | CTSKCTSLCTSBPREPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-05-19 | — | — | US | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-07-02 | — | — | US | disclosed |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10441572-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3514158-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-08-17 | — | — | US | disclosed |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-08-17 | — | — | US | disclosed |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2016-05-05 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| WO-2014120800-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| CN-1079792-C | DP-IV-serine protease inhibitors | FERRING BV (NL) | 2002-02-27 | — | — | CN | disclosed |
| US-6201132-B1 | INHIBITORS OF MEMBRANE-BOUND SERINE PROTEASE; AMINOACYL COMPOUNDS | FERRING B.V. (NL) | 2001-03-13 | — | — | US | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| US-5939560-A | AMINE COMPOUNDS AS ENZYME INHIBITORS | FERRING B.V. (NL) | 1999-08-17 | — | — | US | disclosed |
| EP-0731789-A1 | DP-IV-SERINE PROTEASE INHIBITORS | FERRING B.V. (NL) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015309-A1 | DP-IV-SERINE PROTEASE INHIBITORS | FERRING B.V. (NL) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-10441572-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | CTSK 4565/4885CTSL 4336/4885CTSB 4725/4885 |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CTSK 4114/4885CTSL 3751/4885CTSB 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.